Benzinga | Oct 28, 2020 04:58AM EDT

SVB Leerink Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $115

SVB Leerink analyst Joseph Schwartz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Outperform and raises the price target from $110 to $115.